Dr. Mates has been the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989-1998 Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. She has served on several boards, and recently completed a board membership and a two-year chairmanship of the Board of the New York Biotechnology Association. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland and the board of directors of Gilda's Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.

Recent Stock Transactions by Sharon Mates Ph.D.
Date Type Shares Traded Price Range
Jan 5, 2017 Automatic Sell 4,081 16.55
Jan 4, 2017 Option Execute 6,603 n/a
Dec 11, 2015 Automatic Sell 51,500 53.56 - 55.08
Dec 11, 2015 Option Execute 68,750 0.60 - 1.50
Nov 28, 2014 Sell 35,000 14.75
Nov 25, 2014 Option Execute 50,000 0.50
Aug 29, 2013 Statement of Ownership 0 n/a

Mr. Halstead has been the Senior Vice President, General Counsel of ITI since July 2014. From July 2005 until December 2013 Mr. Halstead served in a number of leadership positions at Warner Chilcott plc, a leading specialty pharmaceutical company that was acquired by Actavis plc in October 2013.  Most recently he was Senior Vice President, Corporate Development at Warner Chilcott where he directed the company’s corporate development, legal and human resources functions.   Prior to that, Mr. Halstead was an attorney at Davis Polk & Wardwell where he focused his practice on mergers and acquisitions, corporate governance and securities law compliance. Mr. Halstead received his bachelor's degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

Recent Stock Transactions by Michael Halstead J.D.
Date Type Shares Traded Price Range
Jan 5, 2017 Automatic Sell 1,601 16.55
Jan 4, 2017 Option Execute 3,107 n/a
Nov 6, 2014 Buy 13,000 15.47
Nov 5, 2014 Buy 7,000 15.21

Dr. Vanover joined the Company in March 2007 and has been Senior Vice President, Clinical Development of the Company since November 2015. Previously, she held various positions since joining in 2007, and has spent over 20 years on the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases including work in the areas of schizophrenia, bipolar disorder and dementia. Dr. Vanover was a Postdoctoral Research Scientist at Lederle Laboratories from 1992 to 1994, Postdoctoral Research Trainee in the Department of Psychiatry at the University of California San Diego from 1994 to 1995, Senior Scientist and Group Leader at CoCensys from 1995 to 2000 and has held various positions as Group Leader and Director at ACADIA Pharmaceuticals from 2000 to 2007.  In these positions, Dr. Vanover participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy, and drug abuse. She has also participated in the discovery and development of Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Vanover received her B.A. in Psychology from the University of Missouri and her Ph.D. in Biopsychology from the University of Chicago.

Dr. Davis has served as Senior Vice President, Chief Scientific Officer since November 2015. Previously, Dr. Davis served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer’s disease; Neurontin, the first drug approved for treating neuropathic pain; and Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.

Recent Stock Transactions by Robert E. Davis Ph.D
Date Type Shares Traded Price Range
Dec 4, 2016 Option Execute 1,757 n/a
Nov 4, 2015 Statement of Ownership 0 n/a

Mr. Hineline has served as Vice President of Finance, Chief Financial Officer and Secretary of ITI since June 2002. From December 2000 to November 2003, Mr. Hineline was the Vice-President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a start-up and was later acquired by Baxter Health Care. Mr. Hineline is a licensed CPA in the State of Maryland and received his Bachelor's Degree from the University of Maryland Baltimore County.

Recent Stock Transactions by Lawrence J. Hineline CPA
Date Type Shares Traded Price Range
Jan 5, 2017 Automatic Sell 1,918 16.58
Jan 4, 2017 Option Execute 3,107 n/a
Dec 15, 2015 Automatic Sell 22,500 51.50 - 52.43
Dec 15, 2015 Option Execute 35,000 1.36 - 1.50
Dec 14, 2015 Automatic Sell 22,500 49.88 - 52.63
Dec 14, 2015 Option Execute 7,500 0.60
Nov 24, 2015 Automatic Sell 5,000 55.00
Nov 24, 2015 Option Execute 5,000 0.60
Dec 9, 2014 Automatic Sell 11,535 16.52
Dec 8, 2014 Automatic Sell 10,965 16.91
Dec 2, 2014 Option Execute 37,200 0.50
Sep 8, 2014 Automatic Sell 300 15.00
Sep 8, 2014 Option Execute 300 0.50
Aug 29, 2013 Statement of Ownership 0 n/a

Dr. Fienberg has served as Vice President of Business Development of ITI since June 2002. He co-founded ITI in May 2002. Dr. Fienberg received his A.B. degree in Genetics from the University of California, Berkeley and his Ph.D. in Human Genetics from Yale University. He completed post-doctoral studies at The Rockefeller University under the direction of Dr. Paul Greengard from 1991-1999. From 1999-2001, Dr. Fienberg was a staff scientist at the Genomics Institute of the Novartis Research Foundation and was appointed a Research Assistant Professor at The Rockefeller University from 2001-2002.

Recent Stock Transactions by Allen A. Fienberg Ph.D.
Date Type Shares Traded Price Range
Sep 9, 2015 Option Execute 12,500 1.36
Aug 21, 2015 Sell 200 30.30
Aug 19, 2015 Sell 10,000 30.30
Mar 31, 2015 Option Execute 12,500 0.60
Jan 14, 2015 Automatic Sell 5,000 19.00
May 28, 2014 Option Execute 37,500 0.50
Aug 29, 2013 Statement of Ownership 0 n/a
Aug 29, 2013 Statement of Ownership 0 n/a

Dr. O’Gorman has been the Vice President of Medical Affairs since December 2014. Dr. O'Gorman has over 10 years of experience in the pharmaceutical industry. Prior to joining Intra-Cellular Therapies, he was the US medical lead for psychiatry at Genentech/Roche where he oversaw the clinical development program of bitopertin for schizophrenia. Before that he spent 5 years at Pfizer representing medical affairs on several branded neuroscience products including Geodon for schizophrenia and bipolar disorder, and Pristiq for major depressive disorder. Dr. O'Gorman received his medical degree from the National University of Galway in his native Ireland, trained in psychiatry at the Maudsley Hospital, at the Institute of Psychiatry (IOP) in London, England and completed his business degree at the New York University Stern School of Business.

Dr. Sanchez has been the Vice President of Corporate Communications and Investor Relations since March 2014.  He has over ten years of experience as a Wall Street research analyst with a deep focus on companies specializing in CNS diseases.  From 2011 to 2014 he was Managing Director of Healthcare Equity Research at Ladenburg Thalmann & Co. From 2008 to 2011 he was Vice President of Healthcare Equity Research at Ladenburg Thalmann & Co. Prior to joining Ladenburg Thalmann & Co. Dr. Sanchez was a Vice President of Equity Research at Punk Ziegel.  Before joining Wall Street, Dr. Sanchez received a Masters of International Affairs from Columbia University in New York and an MBA from University of Los Andes in Bogota, Colombia.  Dr. Sanchez practiced medicine for five years in his native country, Colombia, having received a medical degree from Pontifical Xavierian University.

Dr. Dugar joined the Company as Vice President of Commercial Development in August 2015. Prior to joining ITCI, Dr. Dugar served as Global Head, Clinical Development Science & Innovation at Roche, where he led clinical development teams to advance assets into the Roche pipeline. Prior to Roche, Dr. Dugar was VP, Biosimilars Strategy & Execution for Cardinal Health, a Fortune Top 30 company, and before joining Cardinal Health, he spent time at Pfizer Inc. in positions of increasing responsibility, including Global Head, Medicines Development Group for Biosimilars. Additionally, he also held positions in Commercial Development, as Chief of Staff and Business Operations lead for the Specialty Care Business Unit, as Senior Medical Director for Specialty Neuroscience, and as Market Access & Reimbursement Lead for Pfizer Neuroscience & Ophthalmology. During his career, he has supported and/or led the launch of several drugs, including Geodon/Zeldox and Elelyso/Uplyso. Dr. Dugar received his Ph.D. in Pharmacology from The Pennsylvania State University (PSU) School of Medicine and his M.B.A. from the PSU School of Business. He completed a post-graduate Fellowship in Pharmacoeconomics & Outcomes Research at the University of Michigan.

Dr. Wennogle has served as Vice President, Drug Discovery of ITI since January 2003. For the past 33 years, Dr. Wennogle has been involved in research and development in the pharmaceutical industry aimed at the discovery of novel pharmaceutical entities for human diseases. He was a Staff Scientist and Principal Research Fellow at Ciba-Geigy and Novartis Pharmaceutical Corporation for 19 years, where he led drug discovery programs for CNS disorders, cardiovascular diseases, diabetes and inflammation. Dr. Wennogle received his B.A. from Ithaca College and his Ph.D. in Biochemistry from the University of Colorado, Boulder. He then completed two post-doctoral positions, one at the University of Colorado and the second at the Pasteur Institute in Paris, France, working under Jean-Pierre Changeux on the structure-function of the nicotinic acetylcholine receptor.

Recent Stock Transactions by Lawrence P. Wennogle Ph.D.
Date Type Shares Traded Price Range
Jun 8, 2015 Automatic Sell 25,000 26.84
May 19, 2015 Option Execute 47,500 0.60 - 1.50
Oct 16, 2014 Automatic Sell 5,152 15.00
Oct 15, 2014 Automatic Sell 2,004 15.00
Oct 13, 2014 Automatic Sell 1,600 15.00
Oct 8, 2014 Automatic Sell 4,745 15.00
Oct 6, 2014 Automatic Sell 636 15.00
Oct 3, 2014 Automatic Sell 15,863 15.00
Sep 15, 2014 Automatic Sell 5,000 15.00
Jul 21, 2014 Option Execute 37,500 0.50
May 27, 2014 Sell 5,000 15.00
May 22, 2014 Sell 6,000 14.99 - 15.00
Dec 16, 2013 Option Execute 12,500 0.30
Aug 29, 2013 Statement of Ownership 0 n/a

Stock transaction information provided by EDGAR Online. Intra-Cellular Therapies Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.